No products in the cart.
Source: Aditya Bardia, et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. DOI:
In a new study published in the International Academic Journal Journal of Clinical Oncology, the researchers conducted a Phase 2 clinical trial of an antibody-drug conjugate consisting of a chemotherapeutic drug and target tumor cell surface Molecular antibody composition for the treatment of metastatic triple negative breast cancer has brought new hope.
“This approach represents a new strategy for treating this refractory disease,” says Aditya Bardia, author of the article.
Triple-negative breast cancer is a class of invasive cancer, chemotherapy is the treatment of these diseases, the standard treatment options, but only 15% to 20% of patients with metastases can respond to chemotherapy drugs, and drug response is difficult to continue, the patient’s average The survival time is only 10 to 13 months. Trop-2 is a molecule that is overexpressed in several malignancies, including most triple-negative breast cancers, and thus it becomes a very attractive target for cancer.
The newly developed antibody-drug conjugate is called Sacituzumab govitecan, which contains an antibody that targets Trop-2 and an active ingredient called a chemotherapeutic agent called irinotecan, which can cause significant gastrointestinal Road side effects are therefore limited in application.
Animal studies have shown that this new drug can have a strong effect on transplanted tumors, with other breast cancer treatment drugs in combination with a stronger effect, and a clinical trial also achieved the desired results.
According to the JCO article, a total of 69 metastatic triple negative breast cancer involved in the clinical detection of Sacituzumab govitecan, all patients have received at least one treatment, most people received a variety of treatment. In this study, intravenous administration was performed on day 1 and day 8 with a 21-day cycle. If the patient was able to benefit from treatment, if the patient’s tumor progressed, severe side effects occurred or the patient and attending physician chose to terminate Stop treatment.
At the end of the study, a total of 21 patients had a 30% or more reduction in the number of tumors, 2 of whom had complete remission, and 9 patients continued for at least 12 months of treatment, and about 70% of the patients There was a significant tumor atrophy. Patients responded less than two months after receiving treatment for an average of about nine months and three patients lasted for at least 20 months. The overall survival rate of patients reached an average of 16.6 months, side effects can be controlled by appropriate treatment.
“We have seen very exciting results in these patients, the toxic effects of this drug within the controllable range, so you can continue to administer.It is also necessary to study the patients at an early stage, also need to study and The combined use of other drugs and the availability of treatment for other types of breast cancer, “Professor Bardia said.